

Ayudas Proyectos Generales AECC 2023

Adjudicatarios

Dr. Luis Álvarez Centro Nacional de Investigaciones Oncológicas (CNIO)	Generation of dual STAb-T cells targeting intracellular and cell surface tumor-associated antigens to overcome the clonal heterogeneity of solid tumors
Dr. Toni Gabaldón Instituto de Investigación Biomédica (IRB Barcelona)	Metagenomic profiling from fecal immunochemical test tubes to identify early players and diagnostic markers in colorectal cancer
Dr. Antoni Celia Instituto Hospital del Mar de Investigaciones Médicas (IMIM-Hospital del Mar)	Sensitizing ER+ breast cancer to immune-checkpoint blockade therapy
Dr. Miguel Quintela-Fandino Centro Nacional de Investigaciones Oncológicas (CNIO)	Assessment of the stimulated immune signaling pathways status and its relationship with response to immunotherapies and ADCs in triple-negative breast cancer
Dr. Pablo Menéndez Instituto de Investigación Contra la Leucemia Josep Carreras (IJC)	Next generation, off-the-shelf, CD1a/CCR9-directed dual CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
Dr. Jose Ignacio Martín Fundació Clínic per a la Recerca Biomèdica-IDIBAPS	Exploring the biological and clinical impact of de novo chromatin activation in chronic lymphocytic leukemia
Dr. Mario Fernández Centro de Investigación de Nanomateriales y Nanotecnología (CINN)	Machine learning discovery and integration of multi-omics biomarkers to prevent unexpected recurrence and to avoid unnecessary chemotherapy in women with endometrial cancer

Dra. Aura Carreira

Centro de Biología Molecular "Severo Ochoa" (CBM)

Development of BRCA2-PARP1 interaction inhibitors (B-Pi) as radiosensitizers for homologous recombination proficient breast tumors

Dr. Miguel López

Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS)

sEVs as an innovative nanomedicine approach to treat cancer cachexia by targeting the hypothalamus

Suplentes

Dr. Raul Miguel Luque

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

Identification of novel diagnostic, prognostic, and/or therapeutic targets in oligodendrogliomas associated with the dysregulation of gene expression and genomic instability mechanisms

Dr. Luis Montuenga

Cancer Center Clínica Universidad de Navarra (CIMA-CCUN)

Tumor metabolism- and Immune-related circulating proteins as biomarkers for nodule risk assessment in the context of lung cancer screening

Dr. Mariano Barbacid

Centro Nacional Investigaciones Oncológicas (CNIO)

Precision medicine for pancreatic cancer